Anti-CD74 (clone hLL1)-SMCC-Dox ADC

  • 1.00 Dollar US$
  • Published date: November 16, 2017
    • New York, New York, United States

This ADC product is comprised of an anti-CD74 monoclonal antibody (clone hLL1) conjugated via a SMCC linker to DOX. The DOX is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DOX binds to DNA, causes DNA damage.

Disulfide Linkers, are extensively exploited as a chemically labile linkage. Since the release of disulfide-linked drugs requires a cytoplasmic thiol cofactor, such as glutathione (GSH). Disulfides maintain stable at physiological pH and only when ADCs are internalized inside cells, the cytosol provides reducing environment including intracellular enzyme protein disulfide isomerase, or similar enzymes, drugs can be released.

Doxorubicin is the generic name for the trade name drug, Adriamycin®, as well as, Rubex®, which is a type of anti-cancer chemotherapy drug called an anthracycline. Doxorubicin works by blocking an enzyme called TopoisomeraseⅡthat cancer cells need to divide and grow.

Result 0 votes
Jerry Carter
1 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • E. coli Galactosidase alpha [His]

    E. coli Galactosidase alpha [His]

    Drug Development Shirley (New York) October 25, 2019 10.00 Dollar US$

    Alpha-galactosidase is a glycoside hydrolase enzyme that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. It is encoded by the GLA gene. This enzyme is a homodimeric glycoprotein that hydrolyses the terminal alpha...



    Drug Development Kyiv (Kyiv reg) October 7, 2019 Check with publisher

    Otava Research Institute is pleased to share with new launched services and products for your drug discovery research projects. End-To-End Computer Aided Drug Discovery Services Using our 250,000+ compounds collection and proprietary software we can ...

  • M. Tuberculosis CFP10

    M. Tuberculosis CFP10

    Drug Development Shirley (New York) September 24, 2019 10.00 Dollar US$

    CFP10 is an antigen that contributes to the virulence Mycobacterium tuberculosis. CFP-10 forms a tight 1:1 heterodimeric complex with 6kDaA early secreted antigen target (ESAT-6). In the mycobacterial cell, these two proteins are interdependent on ea...